Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
|Articles|April 1, 1997
The American Journal of Managed Care
- April 1997
- Volume 3
- Issue 4
Abdominal Aortic Aneurysm
Advertisement
Articles in this issue
over 29 years ago
Consideration in Pharmaceutical Conversion: Focus on Antihistaminesover 29 years ago
Issues in the Measurement of Satisfaction with Treatmentover 29 years ago
HMOs and the Efficiency of Healthcare Deliveryover 29 years ago
Reducing Malpractice Risk Through More Effective CommunicationAdvertisement
Related to this article
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.
Systematic review finds combined immunonutrition (arginine, omega-3s, glutamine) in colorectal cancer surgery may cut surgical site infections, while single supplements show no benefit.
FACT Accreditation lets Tennessee Oncology bring community oncology CAR T-cell therapy closer to home, expanding access for non-Hodgkin lymphoma patients.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
Overcoming Barriers to Precision Care and Patient Access
5